Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 7/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.38 |
| ▸ | DRD2 | P14416 | 5/20 | 0.38 |
| ▸ | DRD3 | P35462 | 5/20 | 0.38 |
| ▸ | DRD4 | P21917 | 4/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3054265 | 0.82 | AOC3 (0.47) | AOC3DRD2DRD3DRD4 | |
| SCHEMBL16827516 | 0.78 | AOC3 (0.44) | AOC3DRD2DRD3 | |
| SCHEMBL4508979 | 0.77 | GRM5 (0.58) | AOC3 | |
| SCHEMBL3051636 | 0.77 | ESR1 (0.52) | AOC3DRD2DRD3CYP11B1CYP11B2 | |
| SCHEMBL8230310 | 0.76 | AOC3 (0.53) | AOC3CHRM1DRD2DRD3DRD4 | |
| SCHEMBL4490327 | 0.73 | HRH3 (0.46) | AOC3 | |
| SCHEMBL7799399 | 0.71 | ITGB3 (0.64) | — | |
| SCHEMBL1020534 | 0.71 | AOC3 (0.36) | AOC3CHRM1DRD2DRD3DRD4 | |
| SCHEMBL25306706 | 0.71 | AOC3 (0.57) | AOC3DRD2CYP11B1CYP11B2P2RX7 | |
| SCHEMBL3656341 | 0.71 | DRD2 (0.48) | AOC3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222363-A1 | Bicyclic Derivatives as P38 Inhibitors | PALAU PHARMA, S.A. (ES) | 2010-09-02 | — | — | US | disclosed |
| US-20090286775-A1 | Bicyclic Derivatives as P38 Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-11-19 | — | — | US | disclosed |
| EP-1917241-A2 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | Palau Pharma, S.A. (ES) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007000339-A1 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007000337-A1 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222363-A1 | Bicyclic Derivatives as P38 Inhibitors | MAPK1, MAPKAPK2, MAPK7 | AOC3 3677/4885CHRM1 4478/4885DRD2 4522/4885 |
| US-20090286775-A1 | Bicyclic Derivatives as P38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPKAPK3 | AOC3 3661/4885CHRM1 4477/4885DRD2 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.